Thrombolytics and Intermediate Risk PE

00:00
29:45

Playback Speed

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Nurses Edition Commentary

Mizuho Morrison, DO, Lisa Chavez, RN, and Kathy Garvin, RN
00:00
01:59

Playback Speed

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

James B. -

Where does catheter directed thrombolytics fit into this discussion? Are there any trials to suggest benefit over systemic thrombolytics?

Jason S. -

Could you list references for the comment made by Dr. Kline " The risk of death increases from 2% to 20% with the increase in troponin" in response to the question: Should thrombolytics be given to the patient in Case 3 if she had an increase in her troponin, and initially started out with a negative troponin.?

HARISIOS T. -

With regards to the heterogeneity of individual response to thrombolytics, is there utility in using thromboelastography to help guide lytic therapy?

Angela L. -

Are the troponin values that predict worse outcome/ need for thrombolytics the same as those that are used to diagnose NSTEMI. What are the BNP cut offs used to predict worse outcome and do they change based on any patient factors?

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.